Legend Biotech jumped Monday after the company said its J&J-tied multiple myeloma drug, Cavykti, cut the risk of death.

Johnson & Johnson has reported data from the Phase III CARTITUDE-4 clinical trial where CARVYKTI (ciltacabtagene autoleucel), ...

After putting on a strong performance in preventing disease progression in the earlier treatment of multiple myeloma, Johnson ...

In a report released yesterday, Kostas Biliouris from BMO Capital maintained a Buy rating on Legend Biotech (LEGN – Research Report), ...

Johnson & Johnson and Legend Biotech presented new data from the Phase 3 CARTITUDE-4 study, showing Carvykti significantly ...

Johnson & Johnson reported long-term Phase III CARTITUDE-4 study results showing that a single infusion of Carvykti ...

Legend Biotech (LEGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mitchell ...

Johnson & Johnson linked Carvykti to a 45% reduction in risk of death and Darzalex to a 61% improvement in minimal residual ...

Bristol Myers Squibb’s struggling CAR-T therapy Abecma has hit a major setback. | Bristol Myers Squibb’s CAR-T therapy Abecma ...

The CARTITUDE-4 study found that cilta-cel reduced the risk of death by 45% compared to standard of care in patients with multiple myeloma.

Legend Biotech's valuation is conservative, suggesting potential for significant appreciation and growth ahead. Click here to ...

Carvykti (ciltacabtagene autoleucel) is a prescription drug used to treat certain types of multiple myeloma. Carvykti comes as a liquid suspension for intravenous (IV) infusion given just one time.